Publication | Open Access

PPARγ agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms

InflammationTraumatic Brain InjuryNeurodegenerative DiseasesMedicineAnti-oxidative MechanismsNeuropharmacologyBrain-immune InteractionNeuroprotectionNeuroscienceBrain InjuryNeurologyPparγ Agonist RosiglitazoneBrain Injury PreventionPharmacologyNeuroimmunologyOxidative StressNeuroinflammation